ERRATUM

Autologous graft-versus-host disease

M. JOHN KENNEDY and ALLAN D. HESS

Medical Oncology (1995) **12**, 149-156

“In the final paragraph of the section entitled CLINICAL, STUDIES OF CsA-INDUCED AUTOLOGOUS GVHD” in the above manuscript, it was originally reported that the disease-free survival for women with stage IV breast cancer treated with CsA/ γ -IFN after high-dose chemotherapy was 42%, after a median follow up of 4 years. This finding suggested the possibility that outcome might be superior for such patients when compared with historical controls who were treated with high-dose chemotherapy alone. Further analysis of these data has revealed that this is incorrect. It is now apparent that the time to progression is virtually identical for both groups of patients. After a median follow up of around 5 years the progression-free survival for all patients, whether treated with CsA, CsA/ γ -IFN, or no further therapy after high-dose treatment, is between 8 and 20%. These data do not suggest that there is an improved outcome associated with CsA/ γ -IFN treatment after high-dose therapy in this population.”